Fistula treatment represents a major unmet medical need in the
therapy of
Crohn's disease (CD). Current medical
therapies, such as anti-TNF antibody treatments, are often insufficient and do not achieve permanent
fistula closure. Previously published data point toward a critical role for metalloproteinase-9 (
MMP-9)/
gelatinase B in
fistula pathogenesis. The aim of this project was to investigate in detail MMP-9 expression in different
fistula types and to confirm that MMP-9 is a potential target for
fistula therapy in CD patients.Immunohistochemistry for total and active MMP-9,
Cytokeratin 8 (CK-8) and co-staining of active
MMP-9/CK-8 was performed in specimen derived from perianal
fistulas, entero-enteric
fistulas and
fistulas from patients not responding to anti-TNF
therapy. In addition,
fistulas from the xenograft mouse model (anti-TNF treated or untreated) were analyzed.Total and active MMP-9
protein was detectable in cells lining the tracts of perianal and entero-enteric
fistulas. Of note, total and active MMP-9 was also expressed in
fistulas of CD patients non-responding to anti-TNF treatment. Interestingly, we detected considerable co-staining of active MMP-9 and CK-8 in particular in cells lining the
fistula tract and in transitional cells around the
fistulas. Furthermore, total and active MMP-9 are detectable in both anti-TNF treated and untreated xenograft
fistulas.Taken together, our data suggest that MMP-9 is involved in
fistula pathogenesis in CD patients, in
fistulas of different origins and particularly in patients non-responding to anti-TNF
therapy. Our xenograft
fistula model is suitable for in vivo studies investigating a possible therapeutic role for MMP-9 targeting as
fistula therapy.